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Abstract The recently described therapeutic benefits of
the hemodialysate actovegin on neuropathic symptoms in
diabetic patients with symptomatic polyneuropathy suggest
a neuroprotective activity of the drug. To elucidate the
possible cellular mechanism of the pharmacological effects
of actovegin, we investigated its effects on cultured pri-
mary rat neurons in vitro. Primary neurons were cultured
for up to 10 days in the presence of increasing doses of
actovegin (0.3–1,000 mg/l). Total cell number, dendrite
length and the number of excitatory synapses, i.e., the
amount of the synaptic V-Glut1 protein, were measured by
immunocytochemistry followed by fluorescence micros-
copy. The apoptotic level in neurons after induction of
apoptosis by amyloid peptide Ab25–35 was assessed by the
level of activated caspase-3. In addition, the capability of
the neurons to diminish oxidative stress was assessed by
measuring the cellular level of reactive oxygen species
ROS in the presence of actovegin. Actovegin treatment
yielded an increased maintenance of neuronal cells and
total number of synapses and could lower the level of
activated caspase-3 in a dose-dependent manner. Dendrite
lengths were not significantly affected. In addition, acto-
vegin reduced the cellular level of ROS in cultured neu-
rons. The cellular effects observed suggest neuroprotective
and anti-oxidative effects of the drug Actovegin, which
could at least partially explain its therapeutic benefits.
Keywords Apoptosis  Diabetic polyneuropathy 
Hemodialysate  Neuroprotection  Oxidative stress
Introduction
Diabetic distal symmetric polyneuropathy (DPN) affects
approximately one-third of diabetic patients and is associ-
ated with substantial morbidity including excruciating
neuropathic pain and foot ulcers leading to amputation
(Ziegler et al. 2008; Boulton et al. 2005). Analgesics are
effective in the treatment of neuropathic pain (Dworkin
et al. 2007), but do not slow down the progression of the
underlying neuropathy (Boulton et al. 2005). Various
therapeutic approaches to treat DPN have been developed
(Cameron et al. 2001), which address the pathology of the
disorder, rather than just relieve pain (Ziegler et al. 1995;
Boulton et al. 2005; Chalk et al. 2007). However, despite
apparent recent progress, a potent sustainable therapy of
DPN still remains an unsolved medical need.
Actovegin, a deproteinized hemodialysate produced from
calf blood, containing low molecular weight compounds
of up to 5,000 Da, has been shown to have substantial
therapeutic benefits in DPN. Recently, a randomized,
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double-blind, placebo-controlled clinical trial with sequen-
tial intravenous and oral actovegin treatment of 567 patients
with DPN was conducted over a period of 160 days (Ziegler
et al. 2009). Actovegin treatment significantly improved
neuropathic symptoms like vibration perception threshold,
sensory function and quality of life of the DPN patients. The
hemodialysate is approved as a drug (Actovegin) in a
number of countries and is applied to treat diabetic poly-
neuropathy and other diseases (for review see: Buchmayer
et al. 2011).
The goal of the present investigations was to elucidate
the cellular effects, by which actovegin may exert its
beneficial therapeutic effects in DPN. Well-known phar-
macological actions of actovegin are the stimulation of
oxygen absorption, oxygen utilization, and cellular energy
metabolism (Obermaier-Kusser et al. 1989; Buchmayer
et al. 2011). Furthermore, it exerts insulin-like activity,
such as stimulation of glucose transport, pyruvate dehy-
drogenase and glucose oxidation (Jacob et al. 1996).
Because of these properties, actovegin has previously
been used for treatment of cerebral vascular and degen-
erative disorders (Kanowski et al. 1995; Herrmann et al.
1992). In addition, hemodialysates administered as infu-
sions have shown beneficial effects on the clinical signs
of dementia (Schlaffer et al. 1991; Beiswenger et al.
2008), which may indicate regenerative effects on neu-
ronal tissue.
The present experimental approach was based on ear-
lier studies with a rat model of diabetic polyneuropathy,
which showed a reduction in intraepidermal nerve fiber
density in skin biopsies, as well as a decrease in the loss
of intraepidermal innervation upon therapeutic interven-
tions (Bianchi et al. 2004). Here, the cellular effects of
increasing doses of the hemodialysate actovegin were
assessed in a neuronal in vitro model, namely in cultures
of dissociated hippocampal neurons from embryonic rat
brains. Cultured embryonic rat neurons constitute an
accepted and relevant model system in the scientific
community and have been widely used to evaluate the
effects of pharmacologic and genetic interventions.
Moreover, well-described culturing protocols and proce-
dures for phenotypic characterization of cultures of
embryonal rat neurons exist (Araujo et al. 2004; Burkarth
et al. 2007; Busciglio et al. 1995; Cambon et al. 2004;
Maar et al. 1997; Neiiendam et al. 2004; Skibo et al.
2005; Walicke et al. 1986). The following morphometric
parameters were measured: the number of viable neurons,
neurite outgrowth and synaptic connectivity. In parallel
experiments, we assessed the anti-apoptotic effect of act-
ovegin by measuring the levels of caspase-3 in response to
amyloid peptide (Ab25–35). In addition, we assessed the
anti-oxidative effect of actovegin by measuring the level
of reactive oxygen species (ROS).
Materials and Methods
Preparation of Neuronal Cultures
Dissociated cultures of rat hippocampal neurons were
prepared according to a standard protocol (Maar et al.
1997). Hippocampal tissue from embryonic day 18 rat
fetuses was collected in sterile Hanks’ balanced salt solu-
tion (HBSS buffer [Invitrogen, Karlsruhe, Germany] con-
taining 7 mM HEPES, pH 7.3) and trypsinized using 19
trypsin–EDTA (PAA, Pasching, Austria) containing
10 mM HEPES, pH 7.3. The serum-free medium and
culture conditions were tailored for the growth of neuronal
cells in order to minimize the growth of contaminating
other, e.g., glial cell types. Combination of nuclear staining
and phase contrast microscopy ensured that the numbers of
cells counted reflect changes in neuronal cell numbers.
Subsequently, tissue was triturated in HBSS–HEPES buffer
until no tissue clumps were visible. Cell number was
determined and 2 9 104 cells/well were seeded in 100 ll
NMEM-B27 medium (Burkarth et al. 2007; Goetze et al.
2003) into poly-L-lysine-coated 96-well plates (Greiner
Bio-One, Frickenhausen, Germany) and cultured at 37C
and 5% CO2.
Actovegin Treatment of Rat Hippocampal Neurons
Rat hippocampal neurons were treated with increasing
doses (0.3, 1, 3, 10, 30, 100, 300, 1,000 lg/ml) of acto-
vegin (Actovegin, Nycomed, Linz, Austria) by the addi-
tion of 50 ll of prediluted stock solution to the cultures,
5 h after plating. A broad dose range was tested, as it was
not possible to define a dose that relates to the dose applied
in the therapy of diabetic patients. Cells were cultivated at
37C and 5% CO2 in a humidified atmosphere. Actovegin
treatment effects were explored with respect to culture
maintenance and synaptic connectivity, neurite outgrowth
and neuroprotection (i.e., protection against Ab25–35-
induced apoptosis). Furthermore, the protection by acto-
vegin from oxidative stress (ROS levels) was tested in the
rat neurons.
Immunocytochemistry
For immunocytochemical labeling of dendrites with anti-
bodies against microtubule-associated protein 2 (MAP2; at
days 3 and 6 of in vitro culture) to be used in subsequent
analysis of neurite outgrowth, and excitatory synapses
(Vesicular Glutamate Transporter 1 (VGlut1); day 10) for
the purpose of assessment of synaptic connectivity, culti-
vated hippocampal neurons were fixed with 4% parafor-
maldehyde in phosphate-buffered saline (PBS) for 15 min
at room temperature.
Neuromol Med (2011) 13:266–274 267
123
Cells were washed once with PBS and then blocked and
soaked with blocking reagent (Roche Diagnostics GmbH,
Mannheim, Germany) containing 0.2% Triton X-100
(Sigma-Aldrich, Steinheim, Germany) for 1 h at room
temperature. Primary antibodies against microtubule-
associated protein 2 (MAP2; Sigma-Aldrich) and vesicular
glutamate transporter 1 (VGlut1; Synaptic Systems,
Go¨ttingen, Germany) were diluted [1:1,000] in blocking
reagent containing 0.2% Triton X-100 and incubated with
the cells at 4C overnight. Cells were washed with PBS,
and primary antibodies were detected with Cy3-conjugated
goat anti-mouse IgG (diluted 1:600; Dianova, Hamburg,
Germany) during a 2-h incubation at room temperature.
Nuclei were stained with Hoechst 33258 (1 mg/ml; Invit-
rogen GmbH, Darmstadt, Germany). The working con-
centration of 1 lg/ml was achieved by a 1:1,000 dilution in
PBS. Cells were washed and stored at 4C until examina-
tion by fluorescence microscopy. Image acquisition was
carried out on a Zeiss Axiovert 200.
Cell Number, Neurite Outgrowth and Synaptic
Connectivity of Rat Hippocampal Neurons
Average neurite lengths of MAP2-labeled neuronal cul-
tures were determined using the ImageJ-Plugin Neurite
Average (Natural and Medical Sciences Institute, Reutlin-
gen, Germany), which employs the principles of stereology
(Ronn et al. 2000). Determination of the number of syn-
aptic connections of VGlut1-labeled neuronal cultures and
counting of cell numbers was carried out using ImageJ’s
Analyze Particles function: http://rsb.info.nih.gov/ij/.
Briefly, Neurite Average projects a virtual grid onto
micrographs of MAP2-labeled neuronal cultures and
determines the number of intersections of this grid with
MAP2-positive dendritic structures. The number of these
intersections corresponds to the degree of dendritic arbor-
ization at a given time point. Micrographs of either Hoe-
chst 33258- or VGlut1-stained neuronal cultures were
thresholded and binearized and the resulting signals were
counted.
Ab25–35 Treatment and Apoptosis Induction of Rat
Hippocampal Neurons
Rat hippocampal neurons were cultivated until day 8, and
cell culture medium was aspirated; 100 ll of Ab25–35 stock
solution (Bachem Distribution Services GmbH, Weil am
Rhein, Germany; 225 lM in cell culture medium) was
added to each well, and desired actovegin concentrations
were adjusted by the addition of 50 ll of a prediluted
actovegin stock solution (final Ab25–35 concentration,
150 lM). Plates were further cultivated until day 10, the
time point for the assessment of apoptosis induction.
Quantitation of apoptotic levels was carried out using the
Caspase-Glo 3/7 Assay (Promega GmbH, Mannheim,
Germany) after induction of apoptosis with synthetic
Ab25–35. The cell culture medium was aspirated at day 10,
and 50 ll PBS was added to each well. Cells were lysed by
addition of 50 ll Caspase-Glo 3/7 reagent and incubation
for 30 min at room temperature. Luminescence signals
(which were proportional to total caspase-3/7 activity)
were recorded using a Pherastar microplate reader (BMG
Labtech, Offenburg, Germany). For normalization pur-
poses, cell numbers were quantitated in cultures set up and
treated with Ab25–35 peptides and actovegin in parallel
using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega). Briefly, medium was aspirated at day 10 and
50 ll PBS was added to each well. Cells were lysed by the
addition of 50 ll CellTiter-Glo Reagent and a 10-min
incubation at room temperature. Luminescence signals
were recorded using a Pherastar microplate reader. Acti-
vated caspase-3 levels were determined on a per-cell basis;
data are reported as activated caspase-3 per cell. Each
iteration of activated caspase-3 determination was nor-
malized to three independent determinations of cell
number.
Measurement of Oxidative Stress
Levels of oxidative stress, i.e., the level of ROS, in rat
hippocampal neurons were determined at day 8 after ter-
tiary-butyl hydroperoxide (TBHP) treatment to induce
ROS production experimentally or day 10 after actovegin
treatment, respectively. In the case of TBHP treatment, cell
culture medium was replaced at day 8 by 100 ll of fresh
NMEM-B27 and different concentrations of TBHP were
added to the cell culture medium by addition of 50 ll of
prediluted TBHP stock solution in NMEM-B27 to achieve
final concentrations of 0.1, 0.2, 0.3, 0.5, 0.8, 1, 2 and
3 mM, respectively. Cells were incubated at 37C and 5%
CO2 for one hour before being subjected to ROS
measurements.
For determination of cellular ROS levels, neuronal
cultures, TBHP or actovegin treated, were washed twice
with prewarmed HBSS buffer, and 50 ll of a 15-lM
c-H2DCFDA stock solution was added after the last
washing step (c-H2DCFDA concentration, 5 lM per well).
Cells were incubated for 25 min at 37C and 5% CO2, and
excess c-H2DCFDA was washed off with prewarmed
HBSS. Fluorescence intensity (proportional to total ROS
content) was measured with a Pherastar microplate reader
using a 485/520 nm filter set. In order to calculate ROS
content on a per-cell basis, cell numbers were quantified in
the same plate, directly following recording of the fluo-
rescent signal using the CellTiter-Glo Luminescent Cell
Viability Assay described above.
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Statistical Analysis
Experimental data sets were analyzed with the help of
Statview 5.0 software (SAS-Institute Inc.) using one-way
analysis of variance and Fisher’s PLSD (protected least
significant difference) post hoc tests. At least three repli-
cates were performed for all experiments. All results are
presented as mean values ± SEM. Data were considered to
be significantly different at P values \ 0.05 (*P \ 0.05,
**P \ 0.01, ***P \ 0.001).
Results
Maintenance of Rat Primary Neurons
Following incubation of primary rat neurons for 10 days in
the presence or absence of actovegin, cell numbers in
actovegin-treated cultures (as quantified using nuclear
staining) were significantly elevated up to 2.4-fold com-
pared with untreated cultures (P \ 0.001 at concentrations
of actovegin greater than 10 lg/ml; Fig. 1a). The increase
Fig. 1 Evaluation of a cell number via nuclei staining and b total
excitatory synapse number via vesicular glutamate transporter 1
(VGlut1) staining on day 10 in vitro following incubation of rat
primary neurons with increasing concentrations of Actovegin (Act.;
0.3–1,000 lg/ml) compared with untreated cells. Each plotted point
represents the mean value obtained from six replicate wells; the error
bars represent the SEM. ***P \ 0.001, **P \ 0.01; Fisher-PLSD
test (comparison with untreated cells). c–f Show corresponding
micrographs of representative cultures at day 10 in vitro treated with
1,000 lg/ml Actovegin or left untreated (scale bar: 200 lm [C],
50 lm [E]). g–n: Representative phase contrast micrographs and
manual determination of neurons in untreated (g–j) and Actovegin
300 lg/ml-treated (k–n) primary neuronal cultures at day 7 and day 9
in vitro, respectively (scale bar in Fig. 1c: 200 lm; scale bars in
Fig. 1e, g, k: 50 lm; DIV = days in vitro)
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in the cell number observed was dose dependent. Micro-
graphs of representative nuclear and synaptic staining of
actovegin-treated and untreated cultures on day 10 are
presented in Fig. 1c–f. Cultures that were inspected at day
7 and 9 in vitro using phase contrast microscopy revealed
an improved maintenance of neuronal cell numbers and an
increase in the density of the dendritic network in actove-
gin-treated compared with untreated cultures; this result
was verified by manual counting of neuronal cells
(Fig. 1g–n).
Synaptic Connectivity of Rat Primary Neurons
An antibody against VGlut1 (a marker protein for excit-
atory presynaptic terminals) was used in indirect immu-
nocytochemistry to label excitatory synapses, the major
synaptic type in the cultures analyzed. After 10 days of
culture, the numbers of synaptic contacts in cultures of
rat primary neurons were significantly elevated up to 3.6-
fold in response to the administration of increasing doses
of actovegin when compared to untreated cultures
(P \ 0.001 at actovegin doses greater than 300 lg/ml;
Fig. 1b). Although the total number of synaptic contacts
increased significantly as a result of an overall elevated
neuronal cell number, the occurrence of synaptic contacts
was not significantly increased by actovegin on a per-cell
basis when compared to untreated cultures (Fig. 2).
There was a decrease at a concentration of 1 lg/ml of
actovegin.
Neurite Outgrowth of Rat Primary Neurons
Neurite outgrowth of primary neurons treated with acto-
vegin was assessed to test for a possible growth-promoting
action. Addition of different doses of diluted actovegin to
cultivated rat hippocampal neurons resulted in no signifi-
cant change in neurite length compared with untreated
cells, when measured after 3 and 6 days of culture (data not
shown).
Neuroprotection of Rat Primary Neurons
We employed Ab25–35 peptides for the induction of apop-
tosis in primary embryonic rat neurons to test for a
potential anti-apoptotic effect of actovegin. Ab25–35 rep-
resents the core fragment of Morbus Alzheimer-associated
Ab1–40 and Ab1–42 amyloid peptides and is attributed to the
latter’s neurotoxicity (Klementiev et al. 2007; Pike et al.
1995). Additionally, intra-cerebroventricular (i.c.v.) injec-
tion of Ab25–35 into rodent brain results in neurotoxic
effects that have been also observed after administration of
full-length Ab1-42 (Maurice et al. 1998; Stepanichev and
Moiseeva et al. 2003a, b, Trubetskaya et al. 2003; Cheng
et al. 2006). Most interestingly, an occurrence of Ab25–35
as a cleavage product of Ab1–40 in the brains of Alzheimer
patients has been described recently (Kubo et al. 2002).
Ab25–35 peptide-induced apoptosis in primary neurons
cultured in the presence or absence of actovegin was
determined by measuring the levels of activated caspase-3.
Cell numbers were determined in cultures treated in par-
allel by using the CellTiter-Glo assay. The aim was to
normalize the levels of activated caspase-3, taking into
account the increase in cell numbers observed with acto-
vegin treatment. In the absence of Ab25–35 peptides, levels
of apoptosis induction in cells treated with increasing doses
of actovegin were not consistently altered compared with
untreated cells (Fig. 3). In the presence of Ab25–35 pep-
tides, rat primary neurons treated with increasing amounts
of actovegin exhibited a significant decline in the induction
of apoptosis (a decrease in the levels of activated caspase-3
per cell; P \ 0.001 at concentrations of actovegin greater
than 300 lg/ml). This was apparent at the mid- to high-
dose range and followed a trend toward dose dependency
(Fig. 3).
Oxidative Stress in Rat Primary Neurons
Preliminary experiments were carried out to test the
suitability of a fluorescence-based assay system using
c-H2DCFDA (5-[and-6]-carboxy-2
070-dichlorodihydro-
fluorescein diacetate, Sigma-Aldrich) as a fluorogenic
indicator to detect ROS in the cultures of primary rat
Fig. 2 Evaluation of vesicular glutamate transporter 1 (VGlut1)/cell
ratio of rat primary neurons as calculated from VGlut1 and nuclear
stainings on day 10 in vitro following incubation with increasing
concentrations of Actovegin (Act.; 0.3–1,000 lg/ml). Signals were
compared with those of untreated cells. Each plotted point represents
the mean value obtained from six replicate wells; the error bars
represent the SEM. **P \ 0.01; Fisher-PLSD test (comparison with
untreated cells)
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neurons used. Treatment of neurons with increasing
amounts of tert-butyl hydroperoxide (TBHP), a common
inducer of ROS production, resulted in significantly ele-
vated levels of intracellular ROS (P \ 0.001 at concen-
trations of TBHP greater than 0.2 mM; Fig. 4a). The
ability of TBHP to induce oxidative stress was dose
dependent, with higher concentrations of TBHP resulting
in higher levels of ROS generation. Thus, the cell-permeant
fluorescent indicator of intracellular oxidative status
c-H2DCFDA was confirmed as a suitable marker in the
determination of levels of ROS in the neuronal culture
system used.
With respect to actovegin treatment, levels of ROS were
determined in neuronal cultures grown for 10 days in vitro
under the influence of actovegin to test for a possible effect
on oxidative stress in neuronal cells. A significant reduc-
tion in ROS content (on a per-cell basis) was detected in
cells cultivated in the presence of increasing amounts of
actovegin (P \ 0.001 at concentrations of actovegin
greater than 0.3 lg/ml; Fig. 4b).
Discussion
In the present study, we used hippocampal neurons cul-
tured from embryonic rat brains as an in vitro model to
study drug effects on neuronal tissues. The neurons were
treated with increasing actovegin concentrations in order to
identify possible cellular effects, which may explain the
beneficial therapeutic effects in patients with symptomatic
diabetic polyneuropathy (DPN).
Briefly, we found that the hemodialysate actovegin has
substantial dose-dependent protective effects on rat neu-
rons over a wide range of concentrations. It significantly
supported the maintenance of cultured neurons by
increasing cell survival and by reducing apoptotic levels
when challenged with the neurotoxic peptide Ab25–35. In
addition, it increased the total number of synaptic con-
nections and decreased the burden of oxidative stress in the
neurons. No significant effect of actovegin, however, was
observed with respect to neurite outgrowth. The protective
effects of actovegin observed in the in vitro model may in
concert contribute to the therapeutic benefits of the drug
Fig. 3 Evaluation of apoptosis induction on day 10 in vitro in rat
neurons cultured in the presence of different concentrations of
Actovegin (Act.; 0.3–1,000 lg/ml) after treatment with 150 lM
Ab25–35 compared to controls. 150 lM Ab25–35 was added on day 8;
control/untreated cultures were included. Each plotted point repre-
sents the mean value obtained from three replicate wells; the error
bars represent the SEM. ***P \ 0.001, **P \ 0.01; Fisher’s PLSD
test
Fig. 4 Evaluation of levels of reactive oxygen species (ROS) in rat
neurons after treatment with a increasing concentrations of tert-butyl
hydroperoxide (TBHP) (0.1–3 mM) and b TBHP (3 mM) or
increasing concentrations of Actovegin (Act.; 0.3–1,000 lg/ml),
compared with untreated cells. Each plotted point represents the mean
value obtained from six replicate wells; the error bars represent the
SEM. ***P \ 0.001, *P \ 0.05; Fisher-PLSD test
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actovegin, which was observed in a clinical trial (Ziegler
et al. 2009). In the respective randomized, double-blind,
placebo-controlled clinical trial, it was recently shown that
sequential parenteral and oral treatment with actovegin was
associated with a positive effect on neuropathic symptoms,
vibration perception threshold, sensory nerve function and
mental health-related quality of life in patients with type 2
diabetes and symptomatic polyneuropathy. Since nerve
ischemia and hypoxia are believed to play a role in the
pathogenesis of diabetic neuropathy, actovegin as a drug
may protect against hypoxic cell injury, as previously
observed in cultured hepatocytes (de Groot et al. 1990).
The results of the clinical study (Ziegler et al. 2009) are in
line with the data obtained in vitro presented herein. The
increased survival and synaptic density of neurons cultured
in vitro in the presence of Actovegin suggest that protec-
tion and enhanced maintenance of neuronal networks may
occur under conditions such as diabetic polyneuropathy or
following trauma and stroke. The anti-apoptotic effect of
Actovegin observed in vitro suggests a neuroprotective
effect in neurodegenerative disorders, such as Alzheimer’s
disease (Schlaffer et al. 1991; Saletu et al. 1990; Semlitsch
et al. 1990; Ziegler 2008).
As the neuronal cultures were derived from rat hippo-
campal tissue, it is possible that non-neuronal cell types
such as astrocytes were present and may have contributed
to the increase in cell numbers observed here. However,
neuronal cells could be readily identified by phase con-
trast microscopy owing to their morphology, and an
expansion of glial cells was not observed either in acto-
vegin-treated or untreated cultures. Moreover, it is unli-
kely that the much higher cell numbers observed after
actovegin treatment were due to an increase in numbers of
non-neuronal cells, as there was no evidence for a change
(i.e., reduction) in synaptic contacts on a per-cell basis as
could have been caused by an increase in the number of
non-neuronal cells.
In order to shed light on the nature of the active prop-
erties of Actovegin, a number of experiments were con-
ducted to assess the effects of treatment of rat primary
neurons with increasing amounts of fetal calf serum (FCS),
which is also derived from calf blood like actovegin. Here,
a slight but statistically insignificant trend toward increased
cell numbers and synaptic connections at submaximal
doses of FCS was observed. This may argue for a stronger
beneficial effect of Actovegin due to an enrichment of the
active physiological substance(s) during the production of
Actovegin.
Although cell numbers were found to be maintained in
the presence of Actovegin, experiments that explored the
induction of apoptosis suggested that there was no effect of
Actovegin per se on reducing apoptosis when assessed on
day 10 of culture in the absence of apoptosis-inducing
agents like amyloid peptides. This apparent discrepancy
suggests that loss of neuronal cells may occur through
mechanisms other than apoptosis.
While analgesic drugs, such as antidepressants, anticon-
vulsants and opioids, are used for the symptomatic treatment
of painful diabetic polyneuropathy, other compounds, such
as antioxidants (alpha-lipoic acid) and aldose reductase
inhibitors, have been developed to address the putative
pathogenetic mechanisms of this condition (Boulton et al.
2005; Ziegler et al. 2004, 2006). Treatment with alpha-lipoic
acid has been shown to reduce oxidative stress in vitro, to
prevent nerve dysfunction in experimental diabetic neuropathy,
and to reduce neuropathic symptoms and deficits in patients
with diabetes (Cameron et al. 1998). Thus, the potential of
Actovegin to reduce oxidative stress levels in vitro as
demonstrated here may at least partially explain its beneficial
effect in patients with diabetes and symptomatic polyneu-
ropathy (Ziegler et al. 2009). Results from previous clinical
studies have demonstrated positive therapeutic effects of
Actovegin on age-associated memory impairment and
dementia (Schlaffer et al. 1991; Saletu et al. 1990; Semlitsch
et al. 1990; Ziegler et al. 2008). Compared with placebo,
Actovegin significantly provided better outcomes in
assessments at the psychopathological, psychometric and
behavioral levels. The experiments employing amyloid
peptides described in the current study not only demonstrate
the benefits of Actovegin in protection against Ab25–35-
induced apoptosis, but also the relevance in the context of
Alzheimer’s disease, in which the accumulation and neuro-
toxic action of amyloid peptides in the brain plays a role in
the development of this neurodegenerative disorder. Inter-
estingly, an increased level of reactive oxygen species (ROS)
has also been observed after experimental addition of these
peptides in earlier studies using Alzheimer’s models.
Although not specifically tested in the present setting, it is
likely that the reduction in apoptosis in the rat neurons is
triggered by a reduction in ROS through Actovegin
(Dumont and Beal 2011; Nunomura et al. 2001).
It should, however, be kept in mind that, despite its
clarity, the relevance of the current in vitro study for the in
vivo beneficial effects of Actovegin observed in patients
with diabetic polyneuropathy is limited and needs to be
further clarified by experimental in vivo approaches
including animal and human studies. It has to be noted that
the highest experimentally used concentrations of Acto-
vegin, which are in the supra-physiological range, have
shown a tendency to be less effective in respect to VGlut-1
expression and cell numbers.
In conclusion, the neuroprotective effects observed in
vitro are in line with the results from previous clinical trials
(Ziegler et al. 2009; Saletu et al. 1990; Semlitsch et al.
1990) and indicate that Actovegin could offer a potential
treatment option for neurodegenerative disorders.
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